• 1. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 2. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 3. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 4. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 5. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699

Introduction to 8-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (CAS No. 41565-83-7)

8-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (CAS No. 41565-83-7) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmacology due to its unique structural properties and potential therapeutic applications. This compound belongs to the class of tetrahydroisoquinolines, which are known for their diverse biological activities and have been extensively studied for their roles in various physiological processes.

The molecular structure of 8-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride consists of a tetrahydroisoquinoline core with a methyl group at the 8-position and a hydrochloride salt. The tetrahydroisoquinoline scaffold is a privileged structure in medicinal chemistry, often found in natural products and synthetic compounds with a wide range of biological activities. The presence of the methyl group at the 8-position can significantly influence the compound's pharmacological properties, including its binding affinity to specific receptors and its metabolic stability.

Recent research has highlighted the potential of 8-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride in various therapeutic areas. For instance, studies have shown that this compound exhibits potent neuroprotective effects, making it a promising candidate for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The neuroprotective activity is attributed to its ability to modulate neurotransmitter systems and reduce oxidative stress in neuronal cells.

In addition to its neuroprotective properties, 8-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride has been investigated for its analgesic effects. Preclinical studies have demonstrated that this compound can effectively alleviate pain by interacting with opioid receptors in the central nervous system. This makes it a potential alternative to traditional opioid analgesics, which are associated with significant side effects such as addiction and tolerance.

The pharmacokinetic profile of 8-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride has also been studied extensively. Research indicates that it has favorable oral bioavailability and a relatively long half-life, which are desirable properties for a drug candidate. These characteristics suggest that it could be administered orally with minimal dosing frequency, enhancing patient compliance and convenience.

Safety and toxicity studies have shown that 8-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride is generally well-tolerated at therapeutic doses. However, like any other drug candidate, it is essential to conduct comprehensive preclinical and clinical trials to ensure its safety and efficacy in human subjects. Ongoing research is focused on optimizing the formulation and delivery methods to maximize its therapeutic potential while minimizing any potential side effects.

The synthetic route for producing 8-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride involves several well-established chemical reactions. The process typically starts with the condensation of an appropriate amine and aldehyde or ketone to form the isoquinoline core. Subsequent reduction steps are used to convert the isoquinoline into the tetrahydroisoquinoline scaffold. The final step involves introducing the methyl group at the 8-position and forming the hydrochloride salt.

In conclusion, 8-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (CAS No. 41565-83-7) is a promising compound with diverse biological activities and potential therapeutic applications. Its unique structural features and favorable pharmacological properties make it an attractive candidate for further development in medicinal chemistry and drug discovery. Ongoing research continues to uncover new insights into its mechanisms of action and potential uses in treating various diseases.

• 42923-76-2(6-Methyl-1,2,3,4-tetrahydroisoquinoline)
• 207451-81-8(7-Methyl-1,2,3,4-tetrahydroisoquinoline)
• 14099-81-1(1,2,3,4-Tetrahydroisoquinoline hydrochloride)
• 129961-74-6(8-Methyl-1,2,3,4-tetrahydroisoquinoline)
• 41565-82-6(7-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride)
• 41565-80-4(1,2,3,4-Tetrahydro-5-methylisoquinoline Hydrochloride)
• 7467-63-2(Isoquinoline, 1,2,3,4-tetrahydro-2-(2-phenylethyl)-,hydrochloride (1:1))
• 91-21-4(1,2,3,4-Tetrahydroisoquinoline)
• 123593-99-7(5-Methyl-1,2,3,4-tetrahydroisoquinoline)
• 10166-07-1(Isoquinoline,1,2,3,4-tetrahydro-2-(phenylmethyl)-, hydrochloride (1:1))